Metastatic Colorectal Cancer (Mcrc) Clinical Trials

12 recruitingLast updated: June 17, 2026

There are 12 actively recruiting metastatic colorectal cancer (mcrc) clinical trials across 10 countries. Studies span Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 3. Top locations include Avellino, Italy, Aviano, Italy, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Metastatic Colorectal Cancer (Mcrc) Trials at a Glance

12 actively recruiting trials for metastatic colorectal cancer (mcrc) are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Avellino, Aviano, and Barcelona. Lead sponsors running metastatic colorectal cancer (mcrc) studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, CytoDyn, Inc., and Arbeitsgemeinschaft medikamentoese Tumortherapie.

Browse metastatic colorectal cancer (mcrc) trials by phase

Treatments under study

About Metastatic Colorectal Cancer (Mcrc) Clinical Trials

Looking for clinical trials for Metastatic Colorectal Cancer (Mcrc)? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Colorectal Cancer (Mcrc) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Colorectal Cancer (Mcrc) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 1Phase 2

A Clinical Study of Arfolitixorin in Patients With mCRC

Metastatic Colorectal Cancer (Mcrc)
Isofol Medical AB90 enrolled3 locationsNCT06922383
Recruiting
Not Applicable

Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)

Metastatic Colorectal Cancer (Mcrc)
Rigshospitalet, Denmark150 enrolled4 locationsNCT06938971
Recruiting
Not Applicable

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (Mcrc)
Oncosyne AS75 enrolled1 locationNCT07171554
Recruiting

Fruquintinib in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (Mcrc)
iOMEDICO AG150 enrolled1 locationNCT06787105
Recruiting
Phase 2

The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

Metastatic Colorectal Cancer (Mcrc)
CytoDyn, Inc.60 enrolled7 locationsNCT06699836
Recruiting
Phase 3

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (Mcrc)
University of Campania Luigi Vanvitelli480 enrolled41 locationsNCT07389265
Recruiting
Not Applicable

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

Metastatic Colorectal Cancer (Mcrc)
QIAGEN Gaithersburg, Inc600 enrolled1 locationNCT06645236
Recruiting
Phase 2

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

Colorectal NeoplasmsMetastatic Colorectal Cancer (Mcrc)
Sergey Orlov, MD60 enrolled1 locationNCT06949982
Recruiting
Early Phase 1

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients

Metastatic Colorectal Cancer (Mcrc)
Shanghai Changzheng Hospital9 enrolled1 locationNCT06621173
Recruiting

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

Metastatic Colorectal Cancer (Mcrc)
Arbeitsgemeinschaft medikamentoese Tumortherapie500 enrolled7 locationsNCT06678919
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabMetastatic Colorectal Cancer (Mcrc)+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302